Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT00055926 | CP-724,714 in Treating Patients With Metastatic Breast Cancer | completed | Phase 1 | 9 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu |
| completed |
| Phase 1 |
| 13 |
| Jonsson Comprehensive Cancer CenterOTHER |
| 1 |
| Aug 3, 2020 |
| clinicaltrials |
| NCT01596751 | Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 67 | Hope Rugo, MDOTHER | 1 | Jul 17, 2020 | clinicaltrials |
| NCT03183206 | Safety and Efficiency of γδ T Cell Against Breast Cancer | completed | Phase 1 / Phase 2 | 100 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jul 13, 2020 | clinicaltrials |
| NCT02628132 | Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients | completed | Phase 1 / Phase 2 | 22 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02348320 | Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy | completed | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT02038010 | BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx | completed | Phase 1 | 17 | Northwestern UniversityOTHER | 1 | Jun 29, 2020 | clinicaltrials |
| NCT01803282 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | completed | Phase 1 | 236 | Gilead SciencesINDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03955939 | A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body | completed | Phase 1 | 5 | Eli Lilly and CompanyINDUSTRY | 2 | Jun 1, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT01831089 | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | completed | Phase 1 | 69 | PharmaMarINDUSTRY | 3 | Apr 10, 2020 | clinicaltrials |
| NCT02061332 | DC Vaccine for Patients With Ductal Carcinoma In Situ(DCIS6) | completed | Phase 1 / Phase 2 | 58 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT01320592 | PD0332991/Paclitaxel in Advanced Breast Cancer | completed | Phase 1 | 28 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 8, 2020 | clinicaltrials |
| NCT00002866 | Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer | completed | Phase 1 | 50 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 1, 2020 | clinicaltrials |
| NCT02124148 | A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer | completed | Phase 1 | 167 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 1, 2020 | clinicaltrials |
| NCT00841399 | Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients | completed | Phase 1 | 100 | COL George Peoples, MD, FACSFED | 1 | Mar 31, 2020 | clinicaltrials |
| NCT00854789 | Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer | completed | Phase 1 | 95 | COL George Peoples, MD, FACSFED | 1 | Mar 31, 2020 | clinicaltrials |
| NCT02019524 | Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients(J65) | completed | Phase 1 | 39 | COL George Peoples, MD, FACSFED | 1 | Mar 18, 2020 | clinicaltrials |
| NCT04298333 | Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer | completed | Phase 1 | 18 | Meabco A/SINDUSTRY | 3 | Mar 6, 2020 | clinicaltrials |
| NCT00278109 | Partial Breast Irradiation With Chemotherapy | completed | Phase 1 / Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 19, 2020 | clinicaltrials |
| NCT01355393 | Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT00079157 | Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer | completed | Phase 1 | 28 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT01484080 | Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates | completed | Phase 1 / Phase 2 | 140 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03159585 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | completed | Phase 1 | 6 | Zhujiang HospitalOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT04175171 | Clinical Trial of Comparative Study of GB221 Pharmacokinetics | completed | Phase 1 | 32 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Dec 18, 2019 | clinicaltrials |
| NCT00036790 | Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer | completed | Phase 1 | — | University of Wisconsin, MadisonOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01237067 | Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers | completed | Phase 1 | 77 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02541370 | Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133 | completed | Phase 1 / Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | completed | Phase 1 | 128 | AbbVieINDUSTRY | 1 | Nov 29, 2019 | clinicaltrials |
| NCT01840488 | BN83495 Phase I in Post-menopausal Women | completed | Phase 1 | 50 | IpsenINDUSTRY | 3 | Nov 22, 2019 | clinicaltrials |
| NCT02276300 | HER2-Peptide Vaccination of Patients With Solid Tumors(HER2) | completed | Phase 1 | 2 | Technical University of MunichOTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT03505528 | An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer(Epi-PRIMED) | completed | Phase 1 | 8 | EpiAxis TherapeuticsINDUSTRY | 1 | Nov 13, 2019 | clinicaltrials |
| NCT01783756 | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | completed | Phase 1 / Phase 2 | 9 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01084057 | Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer | completed | Phase 1 | 56 | City of Hope Medical CenterOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT00005858 | LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer | completed | Phase 1 | 25 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT02006979 | Acute Exercise Cardioprotection From Doxorubicin | completed | Phase 1 | 27 | University of British ColumbiaOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02838823 | Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer | completed | Phase 1 | 20 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT01445418 | AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer | completed | Phase 1 | 103 | National Cancer Institute (NCI)NIH | 1 | Oct 22, 2019 | clinicaltrials |
| NCT01100463 | Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome | completed | Phase 1 / Phase 2 | 18 | Nanometics (d.b.a. PHD Biosciences)INDUSTRY | 1 | Oct 8, 2019 | clinicaltrials |
| NCT01861509 | BP-C1 in Metastatic Breast Cancer Patients | completed | Phase 1 | 10 | Meabco A/SINDUSTRY | 2 | Oct 7, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02274623 | Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid | completed | Phase 1 | 33 | OPKO Health, Inc.INDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT01325207 | Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer | completed | Phase 1 / Phase 2 | 34 | Northwestern UniversityOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT02843126 | Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT03346161 | Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach | completed | Phase 1 | 120 | Washington University School of MedicineOTHER | 1 | Sep 6, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Aug 20, 2020source: clinicaltrials